1. Introduction
Myelolipomas are benign, non-functional neoplasms that contain adipose tissue and dispersed hematopoietic elements resembling bone marrow [
1]. They have been infrequently described in humans and several animal species, including dogs and domestic cats [
2,
3].
The etiopathogenesis of myelolipomas is uncertain as it is not clear whether they represent true neoplasms or rather metaplasia (reversible transformation of one differentiated cell type into another due to chronic hormonal stimulation, or chronic inflammatory responses as a result of injuries that involve necrosis, stress or infection), hamartomas (benign-appearing masses composed of cells indigenous to the particular site resulting from aberrant differentiation) or choristomas (normal tissue, for example hematopoietic stem cells, misplaced during embryogenesis) [
4,
5].
The adrenal gland is a predominant location for human myelolipoma, with a handful of reports describing extra-adrenal locations, including the thorax, pelvis and retroperitoneal space [
6,
7,
8,
9]. Whilst adrenal myelolipomas have not been described in cats, there are occasional reports of hepatic myelolipoma and only six reports of splenic myelolipoma in this species [
3,
10].
Myelolipomas are typically small in size and discovered incidentally on advanced imaging or at post-mortem examination [
3,
11]. Whilst mostly an incidental finding, in some cases, large myelolipomas can cause compression on surrounding structures and lead to pain, abdominal discomfort and associated clinical signs of hyporexia and weight loss [
12]. Furthermore, there is a risk that some necrotic lesions may rupture and lead to intrabdominal haemorrhage and shock [
6,
13,
14,
15].
Given the paucity of information about feline myelolipomas, the most appropriate clinical management of this neoplasm in cats is unknown. Extrapolating data from human medicine, conservative watchful surveillance may be appropriate for asymptomatic cats, whilst surgical intervention should be considered in cats where the presence of myelolipoma is associated with abdominal discomfort or in cases of an imminent risk of rupture and hemoabdomen [
16].
In this report, we describe a rare case of splenic myelolipoma, where clinical signs of hyporexia and weight loss were attributed to perceived abdominal discomfort caused by the splenic mass.
3. Discussion
Myelolipomas are rare neoplasms that occur in various animal species and humans and are frequently diagnosed incidentally [
17,
18,
19,
20,
21]. Myelolipomas in cats are reported to be either asymptomatic [
10] or associated with clinical signs such as hyporexia, vomiting, diarrhoea, depression, anorexia and constipation [
3,
20,
22,
23,
24]. In the case presented herein, the main clinical sign was hyporexia. As no other underlying causes of hyporexia have been reliably identified during extensive diagnostic investigations, it was presumed that the mass effect was attributed to an enlarged spleen, leading to reduced appetite and weight loss. The decision was made to remove the spleen surgically with curative intent.
In humans, myelolipomas are also rare and most commonly incidental findings during imaging or autopsy [
7,
11,
25]. The adrenal gland is primarily affected, with rare reports of extra-adrenal locations [
7,
26]. Myelolipomas tend to present without symptoms unless they haemorrhage following rupture or attain a large size. In the latter cases, surgical excision is recommended [
26]. Myelolipomas in cats have been reported in the liver [
10,
20,
22,
23], usually associated with peritoneopericardial diaphragmatic hernias [
20,
23], but are rarely reported in the spleen and have not been described in the adrenal gland.
The myelolipoma presented in this report occurred in a female cat, and previous reports of myelolipomas in domestic cats included eight females [
2,
4,
10,
20,
23,
24] and one male [
22], suggestive of a female predisposition in this species. In terms of breed predisposition, six feline cases of myelolipoma affected Domestic Short and/or Long Hairs [
3,
10,
15,
23,
24] and there are single reports in a Persian [
27] and a Persian cross [
20,
22]. The age of the affected cats ranged from 11 to 16 years old, and the myelolipomas were found in the liver or spleen, either as solitary [
3,
20,
27] or multiple lesions [
3,
22,
23,
24] in the same organ. Splenic myelolipomas have also been reported in cheetah [
17] and in dogs [
18,
21].
Various clinicopathologic abnormalities have been reported in cats with splenic myelolipomas. Hemoabdomen secondary to rupture of a myelolipoma was reported in one cat with a splenic myelolipoma [
2], as well as in a cat with hepatic myelolipoma [
15]. One report described progressive weight loss, tenesmus, and elevated liver enzymes [
24]. Another report described respiratory, gastrointestinal and urinary signs and vocalisation, whilst bloodwork revealed respiratory acidosis with metabolic compensation [
2]. In another case with weight loss as the main clinical feature, the cat had a giant splenic myelolipoma and a concurrent hyperthyroidism [
28]. Overall, the findings in published reports are non-specific for both splenic and hepatic myelolipomas in cats. Accordingly, even though the majority of known causes of hyporexia and weight loss have been excluded in our case, it is difficult to attribute the clinical signs solely to the presence of splenic myelolipoma, as other undetected aetiologies may have contributed to the development of reduced appetite and weight loss.
The diagnosis of myelolipoma is based on a combination of ultrasonographic [
29,
30], cytologic and histopathological findings [
31,
32]. Differential diagnoses for myelolipoma include extramedullary haematopoiesis (EMH), osseous metaplasia, angiomyelolipoma and angiomyomyelolipoma, lipoma and liposarcoma [
5]. Macroscopically, myelolipomas are usually single [
28,
33], but multiple lesions in the same organ [
14,
17,
22,
23] or multicentric myelolipoma [
18] have been described in some species.
The case presented herein showed multiple clinicopathologic abnormalities across serial testing. Initially, only a mild increase in serum ALT activity was noted. This could be due to systemic malaise (e.g. hyporexia, weight loss) causing non-specific hepatocyte necrosis, subclinical chronic hepatitis or hyperthyroidism. Hyperthyroidism was excluded in the case as the Total T4 was normal. On a second set of laboratory results, the ALT serum activity was still increased and slightly higher than in the previous assessment, which may not be clinically significant. Mild hyperglycaemia was most likely attributed to stress, whilst mildly increased CK activity and marginal hypotriglyceridaemia were thought to be insignificant in this case. Free hypercalcemia, a known cause of hyporexia in cats [
34], was evident in our case on the initial screening. PTH and PTH-RP were undetectable, respectively, ruling out hyperparathyroidism and making hypercalcemia of malignancy unlikely. There is no known association between myelolipoma and the development of hypercalcemia in mammals. Whilst idiopathic hypercalcemia of cats could not be completely ruled out in our case, the significance of this abnormality remains uncertain, especially as free calcium has spontaneously normalised one week prior to surgery as demonstrated on subsequent two measurements.
Post-operatively, the PCV dropped from the previous 32% to 30%. This change may be due to blood loss during surgery or haemodilution due to intravenous fluid therapy and does not represent a significant reduction. Hyponatremia and hypokalaemia could be due to excess salivation, as the cat did show ptyalism following surgery. Hypochloraemia may be due to concurrent loss of sodium. This may have caused the ECG abnormalities in the post-operative period. The sudden onset of post-operative hypotension could have been due to post-operative haemorrhage, shock, acidosis, hypothermia, bradycardia, or cardiac failure. The former was ruled out on the ultrasound scan, and underlying cardiac disease was unlikely due to a normal recent echocardiogram. The hypotension, hypothermia and electrolyte disturbances were managed medically, but may have predisposed to thrombus formation which was speculated as a cause of death in this case, albeit short term improvement of clinical parameters.
A small case series showed that splenectomy is well tolerated in the cat, but this study is retrospective and includes various diagnoses which may have an impact on survival [
35]. One case of myelolipoma was included, which had a mean survival time of 339 days (alive at the time of publication) [
35]. The report indicated pre-operative weight loss as a negative prognostic indicator for survival, which may be relevant to our case.
In another study, 5 out of 36 cases (15%) which underwent splenectomy for treatment of a splenic mast cell tumour (MCT) died or were euthanised in the 72 hours following surgery [
36]. The causes of death included cardiopulmonary arrest and suspected degranulation episode. One cat was euthanised due to persistent haemorrhage and suspected disseminated intravascular coagulation (DIC). Reports show that splenectomy can positively impact mean survival times in cats with splenic mast cell tumours (MCTs) [
36,
37]. Splenectomy is consequently considered the treatment of choice for splenic MCTs in cats. However, MCTs are malignant tumours, whereas splenic myelolipomas are considered benign, so the survival times may not be comparable.
There is a risk of death in up to 2% of sick cats undergoing general anaesthesia, and splenectomy also carries a risk of haemorrhage, vascular compromise, arrhythmias, systemic inflammatory response syndrome (SIRS), DIC, hypoxia and ischemia, all of which may be fatal [
38,
39]. Ultimately, the risks of surgery need to be balanced against the risk of hemoabdomen associated with the splenic neoplasm [
2,
15]. There is a scarcity of evidence to support medical versus surgical treatment options in feline patients for splenic myelolipoma due to a lack of long-term follow-up in patients diagnosed with this rare disease.